ChemoStart, the global Insud Pharma initiative designed to accelerate innovation in health, has announced the winners of its 9th edition following the highly anticipated Pitch Day, where 12 finalist startups presented their projects before a panel of experts, investors, and leaders from the biotechnology sector.

 

This year, the program received over one hundred international applications, strengthening its position as one of Europe’s leading initiatives supporting scientific innovation in healthcare.

 

Following the final evaluation, the two winning projects are:

 

Arjuna Therapeutics has developed an innovative new generation of small molecules targeting solid tumours, offering a highly selective therapeutic approach with transformative potential for precision oncology.

 

OrganAID has created a pioneering biotechnology platform that integrates patient-derived organoids with advanced artificial intelligence tools, enabling personalized prediction of drug response and accelerating precision medicine.

 

The winning projects stood out for their scientific impact, clinical translation potential, and their ability to tackle critical challenges in oncology and personalized medicine.

 

The event was inaugurated by Eloísa del Pino Matute, President of the Spanish National Research Council (CSIC), whose participation highlights the program’s relevance within the biomedical innovation ecosystem.

 

ChemoStart, led by Leandro Sigman, reaffirms its commitment to supporting entrepreneurship in the life sciences by offering winners specialized mentoring, access to experts, and valuable strategic connections within and beyond the sector.